(CODX) Co-Diagnostics, Inc. Business Model Canvas Research

Co-Diagnostics, Inc. leans on contract manufacturers and supply-chain vendors to make PCR reagents, assemble portable devices, and source parts, which lets it scale output without building all capacity in-house. This setup also helps keep quality control tighter and fixed costs lighter as demand shifts.

• Supports reagent and device scale-up
• Reduces in-house capacity strain
• Helps control quality and sourcing

Research institutions and test-development collaborators help Co-Diagnostics, Inc. design assays, validate performance, and build new uses beyond human infectious disease. This matters as the Company expands into oncology, agriculture, and vector testing, where outside expertise speeds proof of concept and broadens the pipeline.

• Supports assay design and validation
• Extends use into new testing markets
• Strengthens pipeline diversification

Co-Diagnostics, Inc. must secure approvals, registrations, and local market clearances before each diagnostic can sell, so regulatory execution is a core gate for launch and ongoing revenue. This matters most for clinical and point-of-care products, where country-by-country rules can delay adoption but also protect long-term market access.

• Approvals unlock launch
• Registrations sustain sales
• Local rules vary by country
• Clinical tests face stricter review

Co-Diagnostics, Inc. markets its assays through partners and direct channels, and commercial enablement turns each assay launch into repeat orders. The company also supports rollout with implementation help, training, and technical documents, which lowers adoption friction and helps partners sell into labs faster.

• Global sales through partners and direct channels
• Implementation, training, and documentation support
• Enablement supports recurring assay sales

Co-Diagnostics, Inc. uses a diagnostic test portfolio that spans infectious disease, mosquito screening, and other applications, which broadens its addressable market and supports cross-selling across labs, public health, and research buyers. In 2025, this multi-use base mattered because one platform can serve multiple customer groups, lowering dependence on a single test line.

• Broadens addressable market
• Supports cross-selling
• Spreads demand across uses

Co-Diagnostics, Inc. depends on scientific and regulatory expertise to build PCR assays, validate performance, and clear product registration. These skills are hard to copy, and they support both innovation and commercialization; in 2024, the Company reported $2.7 million in revenue, so execution speed matters.

• Builds PCR assay pipelines
• Supports validation and filings
• Turns R&D into sales-ready products

Co-Diagnostics, Inc. uses one PCR platform across human health, mosquito pathogen screening, liquid biopsy, and agricultural genomics, so the same core tech can reach several end markets. That breadth matters because it spreads demand across diagnostics, public health, and crop testing instead of relying on one use case.

• One platform, multiple markets
• Human, vector, and crop use
• Broader revenue opportunity

Co-Diagnostics, Inc. targets accessible molecular diagnostics with compact systems that can be used in clinics, field sites, and remote settings. That matters where lab infrastructure is thin, because smaller footprints cut deployment friction and let testing move closer to patients.

• Fits low-infrastructure sites
• Supports point-of-need testing
• Improves reach in remote areas

Training for clinical and field users helps Co-Diagnostics, Inc. cut PCR workflow errors and keep device operation consistent, which matters most in portable and point-of-care testing. In 2025, that kind of user support is a direct service lever for higher test accuracy and smoother adoption.

• Guides PCR workflow steps
• Lowers operator error
• Supports point-of-care use

Co-Diagnostics, Inc. can build stickier ties with hospitals, labs, and research users by co-developing and piloting assays, so customer input feeds directly into evidence generation and product refinement. This kind of collaboration supports smoother new product introductions because each pilot can validate performance before wider rollout.

• Co-development builds evidence-linked relationships.
• Pilots help de-risk new assay launches.

Co-Diagnostics, Inc. sells into hospital and lab procurement systems, where tenders, supplier onboarding, and institutional buying decide adoption. This channel matters because diagnostics often move only after validation, contract approval, and budget sign-off at the facility or health-system level.

• Used for large, repeat orders
• Requires tender and onboarding
• Slower, but sticky once approved

Co-Diagnostics, Inc. sells portable and point-of-care testing through partner-led field deployment channels, where implementation partners handle rollout in public health programs, field testing, and remote sites. This matters because practical adoption depends on local training, logistics, and service support, not just the test itself.

• Partners drive field use and onboarding
• Best fit for remote and public health settings
• Supports adoption beyond centralized labs

Research institutions and biotech developers use Co-Diagnostics, Inc. molecular tools to build, test, and validate assays, plus run exploratory work with reagents and platforms. This fits early-stage liquid biopsy, where sensitivity matters and researchers often screen many samples before moving to regulated use.

• Assay development and validation
• Exploratory research use
• Liquid biopsy adoption path

Co-Diagnostics, Inc. also targets agriculture and vector-control organizations, where its PCR tools help detect organisms, traits, and pathogens in crops and mosquitoes. That widens the customer base beyond human diagnostics; WHO says vector-borne diseases make up over 17% of infectious diseases and cause more than 700,000 deaths a year.

• Crop genetics screening
• Mosquito pathogen detection
• Broader, non-human demand

Sales, marketing, and channel support are a real cash cost for Co-Diagnostics, Inc.: global distribution needs commercial staff, partner training, promotions, and account management before products turn into revenue. In recent filings, these costs sit inside SG&A and stay high relative to sales, so every new channel win has to cover more than product delivery.

• Commercial staff and partner support
• Training and promotion spend
• Account management lifts conversion

Co-Diagnostics, Inc. carries recurring general corporate and administrative overhead from public-company reporting, governance, legal, finance, IT, and facilities. These are fixed operating costs that run every year, even when assay sales are uneven, so they put steady pressure on margins and cash flow.

• Public-company compliance costs are ongoing.

• Facilities, legal, finance, and IT add fixed expense.

• Overhead weighs on operating leverage.

Co-Diagnostics, Inc. can widen revenue beyond human diagnostics by selling PCR-based testing into mosquito screening, liquid biopsy research, and agriculture. This matters because its 2025 revenue was still small, so each new segment can lift the total addressable market faster than core clinical sales alone.

• New uses add separate sales lines.
• Mosquito, liquid biopsy, and ag expand reach.
• Non-human markets can scale revenue faster.

Assay development and collaboration revenue comes from paid work with partners on custom tests and joint programs, and it can later feed product launches. For Co-Diagnostics, Inc., this line is valuable because it turns R&D into near-term project income while building assays that can move into future commercialization.

• Partner-funded assay work
• Joint programs can create revenue
• Supports future product sales